Management of postradiation late hemorrhage following treatment for HPV-positive oropharyngeal squamous cell carcinoma

被引:1
|
作者
Stevens, Madelyn N. [1 ]
Gallant, Jean-Nicolas [1 ]
Feldman, Michael J. [2 ]
Sermarini, Anthony J. [3 ]
Cmelak, Anthony [4 ]
Murphy, Barbara [5 ]
Langerman, Alexander [1 ]
Kim, Young [1 ]
Rohde, Sarah L. [1 ]
Mannion, Kyle [1 ]
Sinard, Robert J. [1 ]
Netterville, James L. [1 ]
Chitale, Rohan [2 ]
Topf, Michael C. [1 ]
机构
[1] Vanderbilt Univ, Dept Otolaryngol Head & Neck Surg, Med Ctr, 1215 21st Ave S,7th Floor, Nashville, TN 37323 USA
[2] Vanderbilt Univ, Dept Neurosurg, Med Ctr, Nashville, TN 37323 USA
[3] Vanderbilt Univ, Sch Med, Nashville, TN 37323 USA
[4] Vanderbilt Univ, Dept Radiat Oncol, Med Ctr, Nashville, TN 37323 USA
[5] Vanderbilt Ingram Canc Ctr, Dept Med Oncol, Nashville, TN USA
来源
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | 2022年 / 44卷 / 05期
关键词
hemorrhage; HPV-positive squamous cell carcinoma; oropharyngeal; postradiation; CAROTID BLOWOUT; HUMAN-PAPILLOMAVIRUS; NECK-CANCER; HEAD; TRENDS; RISK;
D O I
10.1002/hed.27001
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Background Acute oropharyngeal hemorrhage is a serious complication for patients with oropharyngeal squamous cell carcinoma (OPSCC), particularly in patients with a history of radiation therapy (RT). Methods Retrospective case series from at a tertiary care center for treated patients with HPV-positive OPSCC presenting with oropharyngeal hemorrhage. Results Median time from completion of chemoradiation to first hemorrhagic event was 186 days (range 66-1466 days). Seven patients (58%) required intervention to secure their airway. All patients were evaluated for endovascular intervention, six (50%) were embolized. Eight patients (67%) had a second hemorrhagic event; median time to second bleed was 22 days (range 3-90 days). Conclusions Acute oropharyngeal hemorrhage is a sequelae following treatment for HPV-positive OPSCC. The majority of bleeds occurred within a year of completion of treatment. While more research is needed to determine optimal treatment paradigms, endovascular intervention should be considered, even if noninvasive imaging does not demonstrate active bleeding.
引用
收藏
页码:1079 / 1085
页数:7
相关论文
共 50 条
  • [31] Outcomes following TORS for HPV-positive oropharyngeal carcinoma: PEGs, tracheostomies, and beyond
    Van Abel, Kathryn M.
    Quick, Melanie H.
    Graner, Darlene E.
    Lohse, Christine M.
    Price, Daniel L.
    Price, Katharine A. R.
    Ma, Dan J.
    Moore, Eric J.
    AMERICAN JOURNAL OF OTOLARYNGOLOGY, 2019, 40 (05) : 729 - 734
  • [32] HPV-Positive Oropharyngeal Carcinoma: A Systematic Review of Treatment and Prognosis
    Wang, Marilene B.
    Liu, Isabelle Y.
    Gornbein, Jeffrey A.
    Nguyen, Chau T.
    OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2015, 153 (05) : 758 - 769
  • [33] HPV-Positive Oropharyngeal Squamous Cell Carcinoma among Patients Taking Adalimumab for Autoimmune Disorders
    Farquhar, Douglas R.
    Taylor, James M.
    Mazul, Angela L.
    Zevallos, Jose P.
    OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2018, 159 (03) : 593 - 594
  • [34] Prospective assessment of multiple HPV-positive oropharyngeal squamous cell carcinomas
    Faden, Daniel L.
    O'Boyle, Connor J.
    Lin, Derrick T.
    Deschler, Daniel G.
    Emerick, Kevin S.
    Varvares, Mark A.
    Faquin, William C.
    Sadow, Peter M.
    Richmon, Jeremy D.
    ORAL ONCOLOGY, 2021, 117
  • [35] Acute Arterial Hemorrhage Following Radiotherapy of Oropharyngeal Squamous Cell Carcinoma
    Greve, Jens
    Bas, Murat
    Schuler, Patrick
    Turowski, Bernd
    Scheckenbach, Kathrin
    Budach, Wilfried
    Boelke, Edwin
    Bergmann, Christoph
    Lang, Stephan
    Arweiler-Harbeck, Diana
    Lehnerdt, Goetz
    Mattheis, Stefan
    Bier, Henning
    Hoffmann, Thomas K.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2010, 186 (05) : 269 - 273
  • [36] Radiation Therapy for HPV-Positive Oropharyngeal Squamous Cell Carcinoma: An ASTRO Clinical Practice Guideline
    Margalit, Danielle N.
    Anker, Christopher J.
    Aristophanous, Michalis
    Awan, Musaddiq
    Bajaj, Gopal K.
    Bradfield, Lisa
    Califano, Joseph
    Caudell, Jimmy J.
    Chapman, Christina H.
    Garden, Adam S.
    Harari, Paul M.
    Helms, Amanda
    Lin, Alexander
    Maghami, Ellie
    Mehra, Ranee
    Parker, Lance
    Shnayder, Yelizaveta
    Spencer, Sharon
    Swiecicki, Paul L.
    Tsai, Jillian Chiaojung
    Sher, David J.
    PRACTICAL RADIATION ONCOLOGY, 2024, 14 (05) : 398 - 425
  • [37] The value of follow-up FDG-PET/CT in the management and prognosis of patients with HPV-positive oropharyngeal squamous cell carcinoma
    Taghipour, Mehdi
    Marcus, Charles
    Califano, Joseph
    Fakhry, Carole
    Subramaniam, Rathan M.
    JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY, 2015, 59 (06) : 681 - 686
  • [38] De-escalating radiotherapy in HPV-positive oropharyngeal squamous cell carcinoma: how much is too little?
    Dodhia, Vikash Hiteshkumar
    Penny, Fiona
    Shanmugasundaram, Ramkumar
    Patel, Nimesh
    BMJ CASE REPORTS, 2024, 17 (01)
  • [39] Radiation therapy dose de-escalation compared to standard dose radiation therapy in definitive treatment of HPV-positive oropharyngeal squamous cell carcinoma
    Gabani, Prashant
    Lin, Alexander J.
    Barnes, Justin
    Oppelt, Peter
    Adkins, Douglas R.
    Rich, Jason T.
    Zevallos, Jose P.
    Daly, Mackenzie D.
    Gay, Hiram A.
    Thorstad, Wade L.
    RADIOTHERAPY AND ONCOLOGY, 2019, 134 : 81 - 88
  • [40] Prognosis of HPV-Positive Oral Squamous Carcinoma: A Cohort Study from Japan
    Goto, Mitsuo
    Hanai, Nobuhiro
    Nishikawa, Daisuke
    Nagao, Toru
    Hasegawa, Yasuhisa
    JOURNAL OF HARD TISSUE BIOLOGY, 2023, 32 (01) : 77 - 82